---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Definition and etiology"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Definition and etiology. Topics: Definition of urticaria, wheals, and angioedema in the international guideline; Classification by duration and by eliciting factors: acute versus chronic at 6 weeks, spontaneous versus inducible; Chronic spontaneous urticaria with known and unknown causes in the guideline classification; Chronic spontaneous urticaria as a share of chronic urticaria in the draft AAAAI/ACAAI JTF guideline; 8 further topics. 12 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition of urticaria, wheals, and angioedema in the international guideline

> “Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both.”
> “A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.”
> “Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-2"></a>

### Classification by duration and by eliciting factors: acute versus chronic at 6 weeks, spontaneous versus inducible

> “Urticaria is classified based on two main criteria: (i) its duration, as acute or chronic, and (ii) the role of definite triggers, categorized as inducible or spontaneous.”
> “Acute urticaria is defined as the occurrence of wheals, angioedema or both for 6 weeks or less.”
> “Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks.”
> “When the clinical course has no definite physical eliciting factor involved and shows a spontaneous course, it is described as chronic spontaneous urticaria”
> “Inducible urticaria is characterized by the presence of definite and subtype‐specific triggers leading to the development of wheals, angioedema, or both”
> “We recommend that urticaria is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks)”
> “We recommend that urticaria is classified as spontaneous (no definite eliciting factor involved) or inducible (specific definite factor involved)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-3"></a>

### Chronic spontaneous urticaria with known and unknown causes in the guideline classification

> “Spontaneous appearance of wheals, angioedema or both for > 6 weeks due to known”
> “CSU comes as CSU with known cause and CSU with unknown cause.”
> “For example, Type I autoimmunity (autoallergy) and type IIb autoimmunity, with mast cell‐activating autoantibodies.”
> “CU patients can concomitantly show more than one form of CU including more than one form of CIndU and they often do.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-4"></a>

### Chronic spontaneous urticaria as a share of chronic urticaria in the draft AAAAI/ACAAI JTF guideline

> “60% of CU have CSU alone”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.2.1.1-5"></a>

### Former name: chronic idiopathic urticaria

> “CU can be classified as chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria and marked by the spontaneous appearance of hives and angioedema due to unknown causes) and chronic inducible urticaria”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.1-6"></a>

### United States: definitions in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “CU is defined as urticaria that has been continuously or intermittently present for at least 6 weeks.”
> “When no underlying cause is found, CU has been referred to as CIU”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.1-7"></a>

### Etiology: autoimmunity as the identified cause of chronic spontaneous urticaria

> “Although CSU pathogenesis is not yet fully understood, it is well established that its signs and symptoms are due to the activation of skin mast cells and the subsequent release and effects of their mediators.”
> “In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types”
> “It is also important to explain to the patient that CU is predominantly an autoimmune condition”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “In conclusion, autoimmunity, either of Type 1 viz. IgE antibodies to local autoallergens, or Type 2b, viz. IgG autoantibodies to IgE or its receptor, are considered to be the most frequent causes of CSU.”

Source: [Church et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29431202/)

<a id="topic-2.2.1.1-8"></a>

### Etiology: infections, malignancy, thyroid disease, food, and drugs

> “Acute urticaria frequently follows upper airways infections”
> “In rare instances, chronic (silent) infections may contribute to CSU, and very rarely, an underlying malignancy has been reported”
> “Other potential underlying causes include active thyroid disease, infections, cancer, inflammatory processes, food, and drugs, though these factors can be both causative as well as aggravating”
> “Intensive and costly general screening programs for causes of urticaria are not advised.”
> “IgE‐mediated food allergy is extremely rarely the underlying cause of CSU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-9"></a>

### Etiology: type 1 allergen sensitization not causal in a Berlin population survey

> “A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.”
> “Prick tests found sensitization of ≥ 1 for type 1 allergens in 39.1% of patients.”
> “These were related to comorbidities such as allergic rhinitis or oral allergy syndrome, but were never the underlying cause of CU, as proven by double-blind, placebo-controlled provocation tests.”

Source: [Zuberbier et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456386/)

<a id="topic-2.2.1.1-10"></a>

### Aggravating factors: NSAIDs, stress, and infections

> “Some patients suffering from CSU experience trigger‐induced augmentation of wheals, angioedema, or both.”
> “Among others, these triggers include stress and infections.”
> “Non‐IgE‐mediated reactions to drugs can also augment the activity of preexisting CSU.”
> “NSAIDs are the most common drugs to do so in up to one‐fourth of patients, except for paracetamol (acetaminophen) and/or COX‐2 inhibitors which are considered to be safer options in patients with CSU.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.1-11"></a>

### Risk factors in an Italian general practitioner database: obesity, anxiety disorders, malignancy, immunosuppressants, and smoking

> “The risk of CSU was statistically significantly higher in the presence of the following variables: obesity; anxiety, dissociative and somatoform disorders; malignancies; use of immunosuppressive drugs; and chronic use of systemic corticosteroids.”
> “History of autoimmune thyroiditis showed a trend towards an increased risk of CSU, though it was not statistically significant.”
> “Smoking was associated with a significantly reduced risk of CSU.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.1-12"></a>

### Children: causes and characteristics similar to adults

> “Recent reports indicate that, in children, the prevalence of CIndUs and CSU, as well as disease characteristics, underlying causes of CSU, and response to treatment, are very similar to those observed in adults”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
